Elsevier

Virology

Volume 146, Issue 2, 30 October 1985, Pages 272-281
Virology

Infection of human T-lymphotropic virus type-1 (HTLV-I)-bearing MT-4 cells with HTLV-III (AIDS virus): Chronological studies of early events

https://doi.org/10.1016/0042-6822(85)90010-8Get rights and content

Abstract

Early events in the infection of the human T-lymphotropic virus type-I (HTLV-I)-positive MT-4 cell line by the acquired immune deficiency syndrome (AIDS) retrovirus HTLV-III were investigated. The virus was adsorbed completely to the cells within 60 min incubation after inoculation of the virus. Then, infected MT-4 cells started to produce the HTLV-III-specific antigens between 12 and 24 hr postinfection. Synthesis of the viral antigens consisting of 120K, 46K, 24K, and 17K polypeptides was suppressed by the treatment of the virus-infected MT-4 cells with cytosine arabinoside (Ara-C) or by the treatment of the virus with anti-HTLV-III-positive sera. The progeny of the virus released from the infected MT-4 cells was titrated by a newly developed plaque-forming assay method and reverse transcriptase activity. The maximum activity of HTLV-III (3 × 105 PFU/ml) was observed on Days 4 and 5 p.i. Most of the viral activities in this preparation were ascribed to HTLV-III, and not to HTLV-I. No phenotypic mixing between HTLV-III and HTLV-I was discerned, although MT-4 cells were HTLV-I-producer cell line. Thus, HTLV-III-infected MT-4 cells are thought to be useful in further study of the interaction between host cells and the virus, and appear to be a good viral source for the analysis of the virus.

References (32)

  • W.C. Goh et al.

    Subcellular localization of the product of the long open reading frame of human T-cell leukemia virus type I

    Science (Washington, D. C.)

    (1985)
  • S. Harada et al.

    Infection of HTLV-III/LAV in HTLV-I carrying cells, MT-2 and MT-4 and application in a plaqueassay

    Science (Washington, D. C)

    (1985)
  • S. Harada et al.

    Quantitative analysis of AIDS-related virus-carrying cells by plaque-forming assay using an HTLV-I-positive MT-4 cell line

    Jpn. J. Cancer Res. (Gann)

    (1985)
  • V.S. Kalyanaraman et al.

    Antibodies to the core protein of lymphadenopathy-associated virus (LAV) in patients with AIDS

    Science (Washington, D. C.)

    (1984)
  • J. Kaplan et al.

    Identification of T cell lymphoma tumor antigens on human T cell lines

    Amer. J. Hematol.

    (1976)
  • D. Klatzmann et al.

    Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes

    Science (Washington, D. C.)

    (1984)
  • Cited by (79)

    • HIV-1 Vif adaptation to human APOBEC3H haplotypes

      2013, Cell Host and Microbe
      Citation Excerpt :

      Cells were maintained at 37°C in a humidified atmosphere of 5% CO2. TZM-bl cells, MT2 T cells, and MT4 T cells were provided by the AIDS Research and Reference Reagent Program (Haertle et al., 1988; Harada et al., 1985; Wei et al., 2002). The adherent cell lines HEK293T and TZM-bl were maintained in Dulbecco’s high-glucose modified Eagle’s medium, supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 50 units/ml penicillin, and 50 μg/ml streptomycin.

    • Novel strategy for anti-HIV-1 action: Selective cytotoxic effect of N-myristoyltransferase inhibitor on HIV-1-infected cells

      2002, FEBS Letters
      Citation Excerpt :

      The reagents used in the study were obtained from the following sources: the RPMI-1640 medium and Dulbecco’s modified Eagle’s medium (DMEM) were from Nissui Seiyaku Co. (Tokyo, Japan); N-myristoyl serinal bisulfite, O-myristoyl serinal bisulfite, N-acetyl-O-palmitoyl serinal diethylacetal, and N-acetyl-O-myristoyl serinal diethylacetal were gifts from Dr. S. Ikeda (Torii and Co., Ltd., Tokyo, Japan). A human T-cell line, CEM, and a chronically HIV-1-infected T-cell line, CEM/LAV-1, were maintained as previously described [19]. A human colon adenocarcinoma cell line, COLO320DM, was cultured at 37°C in DMEM supplemented with 5% fetal calf serum (100 IU/ml penicillin and 100 μg/ml streptomycin) in 5% CO2.

    • Cyclic Zinc-Dithiocarbamate-S,S'-Dioxide blocks CXCR4-mediated HIV-1 infection

      2000, Biochemical and Biophysical Research Communications
    View all citing articles on Scopus
    View full text